What is the most clinically effective and cost effective non-FDG tracer for use in PET-CT for staging and assessment of patients with suspected recurrent prostate cancer?
Healthcare Improvement Scotland.
Scottish Health Technologies Group.
"This advice has been produced following completion of evidence note 67 by Healthcare Improvement Scotland, in response to an enquiry from the Scottish PET-CT Working Group".
Description from online resource; title from PDF caption (Healthcare Improvement Scotland, viewed 5 August 2022)
Prostate